Cyprotex Highlights - May 2020
Read Cyprotex’s new DILI review article published in the Archives of Toxicology entitled 'The Evolution of Strategies to Minimise the Risk of Human Drug-Induced Liver Injury (DILI) in Drug Discovery and Development'.
The article covers DILI liability strategy within the pharmaceutical industry, the importance of drug exposure to contextualising in vitro data and the crucial role played by some hepatic drug transporters.
Read Cyprotex's new joint publication with Unilever on 'Identifying and Characterizing Stress Pathways of Concern for Consumer Safety in Next Generation Risk Assessment'.
The article, published in Toxicology Sciences, covers the development of a cell stress panel consisting of 36 biomarkers for the safety assessment of consumer products.
Last month, Cyprotex joined speakers from Unilever, Proctor and Gamble, Humane Society International and Lhasa for a webinar on ‘The Use of New Approach Methodologies for Cosmetic Safety Assessment without Animal Testing’.
Dr Paul Walker, Head of Toxicology at Cyprotex, presented at the event on 'In Vitro Approaches to Cosmetic Safety Assessment'.
The event was hosted by ASCCT and ESTIV.
Read the latest news from parent company, Evotec:
- Just-Evotec Biologics enters into collaboration with Ology Bioservices on antibodies against Coronavirus
- Consortium provides additional investment for successful LAB150 project focused on rare skin disease called Netherton Syndrome
- Evotec participates in financing round of Exscientia, the world-leading Artificial Intelligence-driven drug discovery company
Telephone:
Europe: +44 (0)1625 505100
North America (East Coast): +1-888-297-7683
Email:
enquiries@cyprotex.com